Orbit Genomics

Executive Summary

Orbit Genomics is a precision medicine company pioneering non-invasive diagnostics through its proprietary, AI-powered OrbiSeq™ platform, which analyzes short tandem repeats (STRs) in repetitive DNA. The platform enables early detection and risk stratification of complex diseases, with an initial focus on a blood-based test for early-stage lung cancer. By leveraging repetitive DNA regions that are often overlooked by conventional sequencing, Orbit Genomics aims to deliver highly sensitive and specific diagnostic tools that could transform cancer screening and monitoring. Founded in 2018 and headquartered in San Francisco, the company operates in the diagnostics space and has not yet disclosed funding rounds or valuation, suggesting it may be in early development or stealth mode. Its technology holds potential for broad applications beyond oncology, including rare genetic disorders and infectious diseases, but clinical validation and regulatory clearance remain key milestones.

Upcoming Catalysts (preview)

• Q4 2026Clinical validation study results for lung cancer diagnostic60% success
• Q3 2026Series A funding round70% success
• Q2 2026FDA breakthrough device designation50% success